Ioflupane (123I)
Clinical data | |
---|---|
Trade names | Datscan, Striascan, Celsunax |
Other names | Ioflupane (FPCIT); [I-123] N-ω-fluoropropyl- 2β-carbomethoxy- 3β-(4-iodophenyl) nortropane |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | N/A |
Excretion | Kidney and fecal |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Ioflupane (123I) is the
Pharmacology
The
Ioflupane has a high binding affinity for presynaptic
Method of administration
The Datscan solution is supplied ready to inject with a certificate stating the calibration activity and time. The nominal injection activity is 185 MBq[7] and a scan should not be performed with less than 111 MBq.
Thyroid blocking via oral administration of 120 mg potassium iodide is recommended to minimize unnecessary excessive uptake of radioiodine.[8] This is typically given 1–4 hours before the injection.[7][9]
The most convenient way to administer the IV dose is via a peripheral intravenous cannula. The scan is carried out 3 to 6 hours post injection.[8][9]
Pharmacokinetics
Blood clearance of the radionuclide is rapid in healthy volunteers.[10] Radioactivity was 4.5% of the injected amount 5 min after injection of ioflupane (123I), falling to 2.2% at 30 min, 1.9% at 5 h, and declining to 1.3% at 24 h and 1.1% at 48 h after injection. Values were similar in both whole blood and plasma. Excretion was primarily renal.
Risks
Common side effects of ioflupane (123I) are headache, vertigo, increased appetite and formication. Less than 1% of patients experience pain at the injection site.[7]
The radiation risks are reported as low. The committed
See also
References
- ^ "Neurological therapies". Health Canada. 9 May 2018. Retrieved 13 April 2024.
- ^ "Datscan- ioflupane i-123 injection, solution". DailyMed. 31 March 2020. Retrieved 23 April 2021.
- ^ "Removal of [123I]Ioflupane From Schedule II of the Controlled Substances Act". DEA Diversion Control Division. Archived from the original on 13 May 2017. Retrieved 2016-02-09.
- ^ "Datscan EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 1 July 2021.
- ^ "Striascan EPAR". European Medicines Agency (EMA). 24 April 2019. Retrieved 1 July 2021.
- ^ "Celsunax EPAR". European Medicines Agency (EMA). 20 April 2021. Retrieved 1 July 2021.
- ^ a b c d e f g "Datscan Summary of Product Characteristics" (PDF). European Medicines Agency. GE Healthcare. 25 July 2019.
- ^ PMID 19838702.
- ^ PMID 22159160.
- PMID 37029298.
- ^ "Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources". ARSAC. Public Health England. 13 February 2019.